Arm CEO predicts AI could enable cancer cure within our lifetimes

René Haas, chief executive of Arm Holdings, one of the United Kingdom’s largest semiconductor designers, told a business‑technology forum that artificial intelligence is poised to drive two breakthroughs within the next decade. He said that, although modelling the interaction of DNA markers with cancer remains “too complex” for current human or computational methods, advances in AI‑driven analytics will eventually enable a cure for cancer within our lifetime. Haas added that the same rapid progress in machine learning could also make widespread deployment of humanoid robots feasible in as little as five years, as AI systems become capable of handling the nuanced perception and decision‑making tasks required for human‑like machines.

The statements come as Arm continues to expand its portfolio of AI‑optimized processor designs, which are increasingly integrated into medical research platforms and robotics prototypes worldwide. Industry observers note that while the timeline for a definitive cancer cure remains speculative, the company’s focus on high‑performance, low‑power chips is aligning with the computational demands of next‑generation AI applications. Haas’s outlook underscores the broader expectation that emerging AI technologies will not only accelerate scientific discovery but also transform everyday interactions through advanced robotics, marking a significant shift in both healthcare and consumer technology sectors.